ADVANCES IN HEPATITIS-A PREVENTION IN TRAVELERS

The introduction of an active vaccine against hepatitis A, the most fr equent of the vaccine-preventable infections in travellers, is an impo rtant contribution to travellers' health. Although theoretically the r isk of exposure may be minimised by taking hygienic precautions, most travellers in practice remain at considerable risk. As compared to imm unoglobulin, vaccine has the advantages of better and long-lasting pro tection. A double-strength vaccine has been introduced (HAVRIX(TM), 14 40 enzyme-linked immunosorbent [ELISA] units [EL.U]) and a single inje ction will protect from day 14 for 1 year. No significant adverse even ts have been reported. Questions that remain unanswered are whether tr avellers leaving before day 14 should receive immune globulin plus vac cine and whether very young travellers should all be immunised. (C) 19 94 Wiley-Liss, Inc.